SEC Form 4 · accession 0001171843-17-005277

IMMUNOMEDICS INC · IMMU

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks · Director

Period of report

Aug 24, 2017

Accepted (ET)

Aug 28, 2017 · 8:54 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000722830

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3,F4	Aug 24, 2017	S	25,000	$10.2442	D	—	I	See Footnote
Common Stock^F4	Aug 28, 2017	S	5,000	$11.45	D	—	I	See Footnote
Common Stock^F3,F5,F4	Aug 28, 2017	S	10,000	$11.5591	D	3,415,578	I	See Footnote
Common Stock^F1	holding	—	—		—	—	D

No Table II lines on this filing.

F1Includes a total of 635,935 shares held as joint tenants by the reporting person and his spouse, Ms. Cynthia L. Goldenberg, also known as Cynthia L. Sullivan, a director of the Company.
F2The price in column 4 is a weighted average price. The prices actually received in this transaction range from $10.15 to $10.31.
F3The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
F4Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.
F5The price in column 4 is a weighted average price. The prices actually received in this transaction range from $11.55 to $11.59.

Chief Scientific Officer and Chief Patent Officer